Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Rhea-AI Summary

Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics' President and CEO Don Cilla will join Aditxt's Weekly Update on April 4, 2025. The event will focus on emerging infectious diseases and provide updates on the Appili transaction and operational highlights.

Key highlights include $117 million in submitted federal funding applications and Appili's track record of securing $33.2 million in prior government awards. The update will also cover modifications to the United States Air Force Academy Cooperative Agreement for ATI-1701, a biodefense vaccine candidate, featuring an increased General & Administrative overhead recovery rate that will be applied retroactively.

Positive

• Secured $33.2M in previous government awards
• Submitted substantial $117M in new federal funding applications
• Increased G&A overhead recovery rate for USAFA agreement, improving financial efficiency

Negative

• None.

Event exploring the increasing risk of emerging infectious diseases

Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications

RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.

Mr. Cilla will join to discuss how Appili is advancing a portfolio of opportunities in the area of public health. The event will also highlight Aditxt’s role as a strategic growth partner, seeking to accelerate promising health innovations and expand access to life-saving treatments worldwide.

Additionally, the discussion will provide insights into Appili’s non-dilutive funding capabilities, highlighting $33.2 million received in prior government awards, $117 million in new funding applications (link to press release), and an update to its United States Air Force Academy (“USAFA”) Cooperative Agreement for ATI-1701, biodefense vaccine candidate. This USAFA update features an increased General & Administrative (“G&A”) overhead recovery rate, applied retroactively to past and future invoices. The increase in the allowable G&A overhead recovery rate represents a potential significant benefit, which would enable Appili to optimize funding resources and advance ATI-1701.

Participants are encouraged to register in advance online:

Registration: Click here to register.

The Company invites participants to engage directly with the Company by submitting questions to engagement@aditxt.com.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

About Aditxt

Aditxt, Inc. ^® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. ("Appili") (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On Dec. 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; expected usage of the Company’s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250402063050/en/

Aditxt, Inc.

Corporate Communications

Jeff Ramson, PCG Advisory, Inc.

T: 646-863-6893

Source: Aditxt, Inc.

FAQ

How much in federal funding applications has ADTX's partner Appili submitted?

Appili has submitted $117 million in federal funding applications, with a proven track record of securing $33.2 million in prior government awards.

When is Aditxt's (ADTX) Weekly Update with Appili CEO scheduled?

The Aditxt Weekly Update featuring Appili CEO Don Cilla is scheduled for April 4, 2025, at 11:30 am ET.

What changes were made to ADTX's USAFA Cooperative Agreement for ATI-1701?

The agreement now includes an increased General & Administrative overhead recovery rate, applied retroactively to past and future invoices for the ATI-1701 biodefense vaccine program.

What will be discussed at the ADTX Weekly Update event?

The event will discuss the urgent need for infectious disease treatments, partnerships in health innovations, Appili's portfolio, and updates on federal funding applications and the USAFA agreement.